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Neuroleptic malignant syndrome is a rare complication when using neuroleptic drugs. We report
the case of a patient with severe Parkinson’s disease who developed neuroleptic malignant
syndrome after withdrawal of his antiParkinsonian medication for elective coronary artery bypass
grafting. Sodium dantrolene may be a therapeutic option in severe cases.
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Neuroleptic malignant syndrome (NMS) is a rare but poten-
tially hazardous complication when using neuroleptic drugs.
We report the case of a fulminant NMS in a patient after
cardiac surgery that was caused by withdrawal of his
antiParkinsonian medication.
Case report
A 61-yr-old man was admitted for elective coronary artery
bypass grafting (CABG). One month before, he had an
inferoposterior acute myocardial infarction that, at the
time, was successfully treated by thrombolysis. He still suf-
fered from angina pectoris despite anti-ischaemic therapy
with a b-blocker, angiotensin-converting enzyme inhibitor
and nitrate. He also had severe Parkinson’s disease, which
was treated with levodopa–benserazide 250 mg and tolca-
pone 100 mg, both taken three times daily. Routine labora-
tory tests, including liver enzymes, were all within the
normal range.
On the day of the operation (day 0) the patient received his
regular morning medication of levodopa–benserazide and
tolcapone and, for sedation, lorazepam. Thiopental was
used to induce anaesthesia and pancuronium was used to
facilitate endotracheal intubation. Anaesthesia was main-
tained with isoflurane and fentanyl. The operation, CABG
using four vein grafts, and the anaesthetic course were
uneventful. After the operation the patient was transferred
to our intensive care unit with a low-dose norepinephrine
infusion rate of 2 to 6 mg min1, which stabilized his mean
arterial pressure between 70 and 80 mm Hg. His trachea was
extubated 14 h after the operation. The thoracic drainage was
900 ml during the first 18 h after the operation, resulting in
a haemoglobin concentration of 9.1 g dl1.
The next morning (day 1), the patient received his regular
oral medication (levodopa–benserazide and tolcapone) in
combination with acetaminophen, aspirin and heparin
sodium. About 2 h later he became pale and sweaty, and
was in distress. The mean arterial pressure fell to 55 mm Hg
without tachycardia and there was no obvious bleeding.
Fluid resuscitation with 500 ml of hetastarch 6% and 800
ml of lactated Ringer’s solution produced no improvement.
Neither increasing the norepinephrine infusion to 10 mg
min1 nor repeated doses of phenylephrine was effective
in elevating the mean arterial pressure. An epinephrine infu-
sion was then initiated, at a rate of 8 mg min1, and the mean
arterial pressure began to improve (70 mm Hg). The hae-
moglobin (9.8–12.1 g dl1) and electrolyte concentrations
(sodium 137–139 mmol l1 and potassium 3.9–4.7 mmol l1)
remained within the normal ranges, but an increasing meta-
bolic acidosis developed despite improvement of the
patient’s blood pressure (for values and time course see
Table 1).
# The Board of Management and Trustees of the British Journal of Anaesthesia 2004
As the metabolic acidosis increased, the patient developed
muscular rigidity and complained of abdominal pain. Clin-
ical examination was indicative of peritonitis. The core body
temperature was 36C and plasma lactate was 19.0 mmol l1
(normal 1.1–2.0 mmol l1). Radiographic examination of
the chest showed a subdiaphragmatic air collection on the
left side. An acute ruptured viscus was suspected and emer-
gency laparotomy was performed under general anaesthesia.
General anaesthesia was induced with etomidate, and
intubation of the trachea was facilitated with succinylcho-
line. During this procedure, the systolic arterial blood pres-
sure fell to a minimum value of 40 mm Hg, but was restored
with repeated doses of epinephrine (1 mg in total), additional
fluid administration and a short period of external chest
compression. Because of the patient’s haemodynamic
instability, anaesthesia was maintained with midazolam
and fentanyl. During laparotomy, no intestinal perforation
or ischaemia was found. Four tumours, each measuring 1 cm
in diameter, were found on the small intestine and resected;
subsequent histological examination revealed a multifocal
low-grade malignant carcinoid tumour. Otherwise the anaes-
thetic course was uneventful, arterial pressure was main-
tained with continuous infusion of norepinephrine and
epinephrine, and no increase in Pco2 was noted during
the intervention.
During surgery, repeated blood gas samples showed
a worsening metabolic acidosis. Because of the patient’s
record of receiving tolcapone and his progressive muscle
rigidity, NMS was suspected and sodium dantrolene was
administered in a dose of 2.5 mg kg1. The acidosis
resolved almost completely within 15 min and the patient’s
cardiovascular status stabilized. After the operation,
mechanical ventilation was continued and the patient
was transferred back to the intensive care unit. The mus-
cular rigidity had resolved and did not return. The remain-
ing acidosis resolved with a single adminstration of 100 ml
of sodium bicarbonate 8.4%. The attending neurologist
continued levodopa–benserazide therapy but withheld tol-
capone after this episode.
Subsequently, the patient suffered from multiple organ
dysfunction syndrome with pulmonary, hepatic, pancreatic
and renal impairment. Blood cultures that were taken before
the abdominal operation showed no growth of microorgan-
isms. The creatine kinase concentration reached a maximum
of 1350 U l1 (normal 50–200 U l1) and the liver enzyme
concentrations peaked on day 3. A needle muscle biopsy
from the left lateral vastus muscle on day 4 showed no
histological necrosis and appeared normal under enzyme-
histochemical examination. The 5-hydroxyindoleacetic acid
concentration, as a marker of the extent of the carcinoid
tumour, was within the normal range. After an initial
improvement of his condition, the patient died unexpectedly
of acute heart failure on day 12.
The postmortem findings revealed an acute myocardial
infarction. No metastases of the carcinoid tumour were
detected. Brain autopsy showed numerous Lewy bodies in
the neocortical region.
Discussion
The incidence of NMS is estimated to be between 0.07 and
2.2% among patients receiving neuroleptic agents,1 with a
mortality of 11%.2 A wide variety of antipsychotic agents,
including phenothiazines, butyrophenones, thioxanthenes,
benzamine, clozapine and risperidone, are reported to be
causal agents for eliciting NMS. It has also been reported
during treatment with tolcapone in combination with
clozapine3 and also after abrupt discontinuation or reduction
of antiParkinsonian medication (e.g. levodopa–benserazide
and tolcapone).4 5 The pathophysiological mechanism of
NMS is unclear but is thought to be an acute dopaminergic
transmission block in the basal ganglia and hypothalamus.1
Antipsychotic agents can cause dopaminergic transmission
block, and this mechanism may also occur following the
Table 1 Laboratory results in a patient with fulminant neuroleptic syndrome after elective heart surgery. ABGA, arterial blood gas analysis; BE, base excess
Day 1 Day 2
6:30 15:10 17:00 17:50 19:00 20:25 22:50 0:30 3:30 7:10 9:50 14:25
ABGA
pH 7.41 7.22 7.02 6.93 7.1 7.11 7.09 7.21 7.26 7.37 7.49 7.51
Bicarbonate (mmol litre1) 27 9 7.3 7.6 8.6 8.1 8.5 10.9 11.2 16.5 21.6 24
BE (mmol litre1) 2.5 –17.4 –22.4 –24.4 –20.4 –20.7 –20.8 –16 –14.5 –7.2 –0.4 2.1
PaCO2 (kPa) 5.8 3 4 5.1 3.8 3.5 3.8 3.7 3.4 3.9 3.8 4.1
PaO2 (kPa) 16.2 25 31 36.6 28.8 13.4 20.8 18.7 18.5 19.7 27.1 19.8
Chemistry
Na (mmol litre1) 140 138 139 139
K (mmol litre1) 4.6 4.8 4.5 4.5
Creatinine (mmol litre1) 210 200 242 270
ASAT (U litre1) 1791 2150 6596 7750
1msp; ALAT (U litre1) 540 641 3711 3625
GGT (U litre1) 20 20 23 24
AP (U litre1) 55 52 68 82
CK (U litre1) 37 621 1350
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abrupt discontinuation of neuroleptic or antiParkinsonian
agents, or the use of dopamine-depleting agents.6
Risk factors for developing NMS are organic brain dis-
ease, mental retardation and catatonia.7 The sympatho-
adrenal hyperactivity in patients seems to play a major
role,7 reflecting an imbalance in the levels of monoamine
metabolites in the cerebrospinal fluid.8 Patients with demen-
tia of the Lewy body type, as found in the postmortem
autopsy of our patient, are even more sensitive to neuroleptic
medication and NMS.9 It is not known whether patients with
dementia of the Lewy body type are also more susceptible to
NMS after discontinuation of antiParkinsonian medication,
but it can be postulated in our case.
The diagnostic characteristics for NMS consist of major
criteria (fever, rigidity and elevated creatine phosphokinase)
and minor criteria (tachycardia, abnormal arterial blood
pressure, tachypnoea, altered consciousness, diaphoresis
and leucocytosis). The diagnosis of NMS can be difficult,
as these symptoms may be missing.10–13 In our patient, the
absence of fever was misleading at the beginning of the
clinical course when hypotension, increasing muscular
rigidity and abdominal pain were the predominant symp-
toms. The clinical findings of increasing pain and acidosis,
together with subdiaphragmatic air collection, led us to sus-
pect a ruptured viscus. Subdiaphragmatic air collection may
be caused by peritoneal perforation and is sometimes seen
after introducing the thoracic drainage in CABG. After the
exclusion of abdominal perforation, the patient’s medical
history, which showed discontinuation of antiParkinsonian
medication, led to the diagnosis. Muscular rigidity is respon-
sible for rhabdomyolysis and the elevation in creatine kinase
concentration during NMS. We did not detect myonecrosis
in the biopsy performed, but histological changes in NMS
are not specific and constant.14 15
The specific time for development of NMS varies, and
may range from hours1 to months.7 In our patient, the first
symptoms developed 26 h after the last administration of
levodopa–benserazide and tolcapone. We suggest two rea-
sons for the early and fulminant course of the NMS in our
patient. First, tolcapone is highly protein bound (>99%) and
the expanded volume of distribution during cardiopulmon-
ary bypass could have led to a rapid fall in plasma con-
centration. Secondly, since gastric emptying is delayed after
CABG, delayed intestinal absorption of the antiParkinsonian
medication after the operation on day 1 may have resulted
in low plasma levels.16 This may explain why the onset
of symptoms started after the regular administration of
levodopa–benserazide and tolcapone on day 1.
The clinical course of NMS is unpredictable. It can range
from altered consciousness and elevated body-core tempera-
ture to myocardial infarction,17 cardiac failure18 and even
multiple organ dysfunction. Our patient presented with
vasodilation and shock of unknown origin, similar to septic
shock, which was unresponsive to fluid resuscitation or to
peripheral vasoconstrictors. After the exclusion of excessive
blood loss with no apparent sign of bleeding and a negative
chest radiograph, the muscular rigidity of the abdominal
wall mimicked peritonitis which could have been an
explanation for the worsening condition of the patient and
led us to suspect a ruptured viscus. Finally, review of the
patient’s medication led to diagnosis after the intraoperative
exclusion of an abdominal problem.
The treatment of NMS depends on early recognition.
General treatment, including hydration, nutrition and reduc-
tion of fever, is essential; and secondary complications (e.g.
hypoxia, acidosis and renal failure) must be treated aggres-
sively. Withdrawal of the neuroleptic agent, if administered
previously, is crucial. Dopamine agonists such as bromo-
criptine and amantadine hydrochloride have been used suc-
cessfully to treat NMS. The use of glutamate receptor
antagonists has also been advocated.19 Sodium dantrolene,
a non-specific direct-acting muscle relaxant used to treat
Table 2 Characteristics of neuroleptic malignant syndrome and malignant hyperthermia.*The presence of all three major criteria, or two major and four
minor manifestations, indicates a high probability of the presence of neuroleptic malignant syndrome if supported by clinical history (e.g. not indicative of malignant
hyperthermia)
Neuroleptic malignant syndrome Malignant hyperthermia
Clinical manifestations Major criteria: fever, rigidity, elevated creatine kinase concentration
Minor criteria: tachycardia, abnormal arterial pressure, alveolar
hypoventilation and tachypnoea, altered consciousness,
diaphoresis, leucocytosis*
Tachycardia, arrhythmias of all type, asystole, increased
expiratory CO2, hyperventilation, spasm of
masseter muscle (trism), fever
Laboratory tests Leucocytosis, elevated creatine kinase Hypoxaemia, metabolic acidosis, hypercapnia,
hyperkalaemia, elevated liver enzymes
(transaminases) and creatine kinase
Therapy Discontinuation of trigger; ranging from supportive therapy for
mild forms to intensive care treatment; some effect of bromocriptine
and amantadine reported; dantrolene for severe cases
Discontinuation of trigger; dantrolene; active cooling
Trigger Neuroleptic drugs, antiParkinsonian medication (including withdrawal) All volatile anaesthetics, succinylcholine
Time course Onset reported after 24–72 h Early onset (minutes) after trigger exposure
Diagnostic Medical history, finally by exclusion In vitro contracture test
Aetiology Loss of regulation of central dopaminergic receptor (hypothesis:
primary sympathoadrenal hyperactivity)7
Primary muscle defect; loss of regulation of
intracellular calcium homeostasis
Genetics Unknown Autosomal dominantly inherited
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malignant hyperthermia, can also be effective in NMS; its
ability to elicit muscle relaxation seems to decrease body
temperature and diminish oxygen consumption. In our
patient, metabolic acidosis significantly decreased after the
use of sodium dantrolene and resolved with the subsequent
single dose of sodium bicarbonate.
NMS occurring perioperatively may prove difficult to
distinguish from malignant hyperthermia as the clinical
course may be very similar (Table 2). In our case, the
delay in onset of symptoms after the discontinuation of
potent inhalational anaesthetics precludes malignant
hyperthermia. Further differential diagnoses of NMS
include neuroleptic-induced heatstroke, acute lethal catato-
nia, monoamine oxidase inhibitor drug interaction, central
anticholinergic crisis and akinetic crisis in the advanced
stages of Parkinson’s disease. The akinetic crisis is charac-
terized by severe rigidity, progressive immobilization with
concomitant hyperthermia, vegetative dystonia and tachy-
cardia. Therefore the severe form of an akinetic crisis is not
easy to distinguish from NMS;19 20 although these two enti-
ties do not differ with regard to symptoms, their therapies
and clinical courses do. Akinetic crisis can develop in
patients at an advanced stage of Parkinson’s disease after
reduction or cessation of dopaminergic therapy.21 We pos-
tulate that the clinical course of our patient provides good
evidence for NMS.
Conclusion
Withdrawal of antiParkinsonian medication in a patient with
severe Parkinson’s disease during elective CABG caused a
fulminant NMS. Haemodynamic instability with metabolic
acidosis, increasing muscular rigidity and abdominal pain
were the main symptoms. Finally, after the administration of
dantrolene, metabolic acidosis decreased significantly,
muscular rigidity resolved and haemodynamic stability was
re-established. Parkinson’s disease is not a rare feature in the
population scheduled for CABG; therefore clinicians must
be aware of this potential complication. Perioperative con-
tinuation of antiParkinsonian medication should be con-
sidered. If levodopa–benserazide and tolcapone are to be
discontinued for the operation, the dose should be reduced
before the operation in a gradual manner, possibly in a
clinical setting.
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